CDER Builds Strong Foundation Of NMEs For 2014 As Approval Total Hits 20
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmaceutical Approvals Monthly takes stock of FDA’s performance at mid-year: CDER only needs to clear eight more novel agents to top 2013 in new molecular entity and novel biologic approvals, and priority and orphan drugs make up a higher portion of novel approvals than in recent years.